TRANSCEND Aftermath: Angiotensin II Type 1 Receptor Antagonists (Angiotensin Receptor Blockers) at the Clinical Crossroad

By Volpe Massimo  

High Blood Pressure & Cardiovascular Prevention, Vol. 16, Iss. 1, 2009-05 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite

Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil

By UNGER THOMAS  

Blood Pressure, Vol. 9, Iss. 1, 2000-05 ,pp. : 14-18

Informa Healthcare

Access to resources Recommend Favorite

Prescription Data Related to the Use of Calcium Channel Blockers, ACE Inhibitors and Angiotensin II Type 1 Receptor Antagonists (Angiotensin Receptor Blockers) in Combination Identify Savings Opportunities

By Carugo Stefano  

High Blood Pressure & Cardiovascular Prevention, Vol. 16, Iss. 1, 2009-05 ,pp. : 21-26

Adis International

Access to resources Recommend Favorite

Is it Possible to Differentiate between Angiotensin II Type 1 (AT1) Receptor Blockers in Normotensive Volunteers?

By AZIZI M.   NICOLET L.   CHATELLIER G.   GUYENE T. T.   HEMPENIUS J.   MÉNARD J.  

Blood Pressure, Vol. 9, Iss. 1, 2000-05 ,pp. : 53-53

Informa Healthcare

Access to resources Recommend Favorite

Pitavastatin Further Decreases Serum High-Sensitive C-Reactive Protein Levels in Hypertensive Patients with Hypercholesterolemia Treated with Angiotensin II, Type-1 Receptor Antagonists

By Yoshika Masamichi   Komiyama Yutaka   Masuda Midori   Yokoi Toyohiko   Masaki Hiroya   Ohkura Hiroe   Takahashi Hakuo  

Clinical and Experimental Hypertension, Vol. 32, Iss. 6, 2010-10 ,pp. : 341-346

Informa Healthcare

Access to resources Recommend Favorite